SPRINT Revisited: Updated Results and Implications.
SPRINT Revisited: Updated Results and Implications.
复制标题
DOI:
10.1161/hypertensionaha.121.17682
复制
发表时间:
2021-12
期刊:
影响因子:
--
通讯作者:
SPRINT Research Group
中科院分区:
文献类型:
--
作者:
Wright JT Jr;Whelton PK;Johnson KC;Snyder JK;Reboussin DM;Cushman WC;Williamson JD;Pajewski NM;Cheung AK;Lewis CE;Oparil S;Rocco MV;Beddhu S;Fine LJ;Cutler JA;Ambrosius WT;Rahman M;Still CH;Chen Z;Tatsuoka C;SPRINT Research Group
The Systolic Blood Pressure Intervention Trial (SPRINT) results have influenced clinical practice but have also generated discussion regarding the validity, generalizability and importance of the findings. Following the SPRINT primary results manuscript in 2015, additional results and analyses of the data have addressed these concerns. The primary objective of this manuscript is to respond to key questions that have been raised. The Systolic Blood Pressure Intervention Trial (SPRINT) demonstrated the effectiveness of treating SBP to levels well below those previously recommended in US and European BP guidelines. The SPRINT results have informed guideline committees in recommending treatment to SBP targets lower than previously advised. However, some of the SPRINT findings have generated discussion, and questions have been raised regarding their application in clinical practice. These include generalizability, validity of the outcome measures (especially heart failure), the methods used for event ascertainment, the effect size of the intervention benefit, and safety and tolerability of the <120 mmHg target. Following the SPRINT primary results publication in 2015, additional reports from SPRINT have addressed many of these concerns. This manuscript reviews evidence for validity and potential clinical implications of the SPRINT findings.